Literature DB >> 9484922

Surgery for gastric remnant carcinoma following Billroth II gastrectomy.

P Lissens1, L Filez, R Aerts, A D'Hoore, E Van Cutsem, N Ectors, F Penninckx, R Kerremans.   

Abstract

Between January 1983 and December 1995, 31 patients with gastric remnant carcinoma were operated on 6-45 years after a Billroth II resection for peptic ulcer disease. Total gastrectomy with Roux-en-Y reconstruction was performed in all cases. In 16 patients (52%) extended resection with removal of one or more adjacent organs was necessary for oncological reasons. In this elderly population with a high incidence of pre-operative risk factors (55%), most tumours were classified as stage III or IV (45%). Although total gastrectomy should be the surgical option of first choice for gastric remnant carcinoma, it resulted in high levels of post-operative mortality and morbidity (13% and 35%, respectively), especially in patients with stage III and IV tumours who underwent resection of an adjacent organ. Despite extended surgery, if necessary, the recurrence rate after 'curative' surgery is high (8/20 patients) and the cumulative disease-free 5-year survival rate was 48%. Detection of the tumour at an earlier stage not only limits the extent of resection and lowers the complication rate, but also improves survival.

Entities:  

Mesh:

Year:  1997        PMID: 9484922     DOI: 10.1016/s0748-7983(97)93013-4

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Risk factors for complications during surgical treatment of remnant gastric cancer.

Authors:  In Gyu Kwon; In Cho; Yoon Young Choi; Woo Jin Hyung; Choong Bai Kim; Sung Hoon Noh
Journal:  Gastric Cancer       Date:  2014-04-05       Impact factor: 7.370

2.  Can we apply the same indication of endoscopic submucosal dissection for primary gastric cancer to remnant gastric cancer?

Authors:  Yoon Young Choi; In Gyu Kwon; Sang Kil Lee; Hyun Ki Kim; Ji Yeong An; Hyoung Il Kim; Jae Ho Cheong; Richard Thomas Mliwa; Sung Kwan Shin; Yong Chan Lee; Woo Jin Hyung; Sung Hoon Noh
Journal:  Gastric Cancer       Date:  2013-05-22       Impact factor: 7.370

Review 3.  Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer Association.

Authors:  Hideaki Shimada; Takeo Fukagawa; Yoshio Haga; Koji Oba
Journal:  Gastric Cancer       Date:  2015-12-14       Impact factor: 7.370

4.  Clinicopathological characteristics and prognosis of remnant gastric cancer.

Authors:  Sang Bong Lee; Jae Hun Kim; Dae Hwan Kim; Tae Yong Jeon; Dong Heon Kim; Gwang Ha Kim; Do Youn Park
Journal:  J Gastric Cancer       Date:  2010-12-31       Impact factor: 3.720

5.  Development and External Validation of Web-Based Models to Predict the Prognosis of Remnant Gastric Cancer after Surgery: A Multicenter Study.

Authors:  Qi-Yue Chen; Qing Zhong; Jun-Feng Zhou; Xian-Tu Qiu; Xue-Yi Dang; Li-Sheng Cai; Guo-Qiang Su; Dong-Bo Xu; Zhi-Yu Liu; Ping Li; Kai-Qing Guo; Jian-Wei Xie; Qiu-Xian Chen; Jia-Bin Wang; Teng-Wen Li; Jian-Xian Lin; Shuang-Ming Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Wei Lin; Qing-Liang He; Chao-Hui Zheng; Chang-Ming Huang
Journal:  J Oncol       Date:  2019-04-10       Impact factor: 4.375

6.  Clinical Outcomes of Totally Laparoscopic Total Gastrectomy versus Open Total Gastrectomy for Remnant Gastric Cancer.

Authors:  Su Jung Choi; Chung Sik Gong; Byung Sik Kim; Seon Ok Kim; Hee Sung Kim
Journal:  J Minim Invasive Surg       Date:  2019-03-15

7.  Propensity score-matching analysis to compare clinical outcomes of endoscopic submucosal dissection for early gastric cancer in the postoperative and non-operative stomachs.

Authors:  Mitsuru Esaki; Sho Suzuki; Yasuyo Hayashi; Azusa Yokoyama; Shuichi Abe; Taizo Hosokawa; Shinichi Tsuruta; Yosuke Minoda; Yoshitaka Hata; Haruei Ogino; Hirotada Akiho; Eikichi Ihara; Yoshihiro Ogawa
Journal:  BMC Gastroenterol       Date:  2018-08-06       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.